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Background: The aim of our study was to review the findings of health insurance fraud investigations and to evaluate their impacts 
on medical costs for target and non-target organizations. An interrupted time series study design using generalized estimation 
equations was used to evaluate changes in cost following fraud investigations.
Methods: We used National Health Insurance claims data from 2009 to 2015, which included 20,625 medical institutions (1,614 tar-
get organizations and 19,011 non-target organizations). Outcome variable included cost change after fraud investigation.
Results: Following the initiation of fraud investigations, we found statistically significant reductions in cost level for target organiza-
tions (–1.40%, p< 0.001). In addition, a reduction in cost trend change per month was found for both target organizations and non-
target organizations after fraud investigation (target organizations, –0.33%; non-target organizations of same region, –0.19%; non-
target organizations of other regions, –0.17%).
Conclusion: This study suggested that fraud investigations are associated with cost reduction in target organization. We also found 
similar effects of fraud investigations on health expenditure for non-target organizations located in the same region and in different 
regions. Our finding suggests that fraud investigations are important in controlling the growth of health expenditure. To maximize 
the effects of fraud investigation on the growth of health expenditure, more organizations needed to be considered as target orga-
nizations.
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INTRODUCTION
Over the past decades, the growth of healthcare spending in 
South Korea has increased rapidly. As a result, healthcare expendi-
tures, which accounted for 2.8% of growth of the gross domestic 
product (GDP) in 1970, increased to 7.2% in 2013, faster than the 
growth of the GDP [1]. The increase in healthcare expenditures 
has been attributed to multiple factors, including aging of the pop-
ulation, the introduction of new technologies, changes in health 
insurance reimbursements, and political changes [2-4]. Given the 
trend of increasing costs and the magnitude of healthcare expen-
ditures, this issue has been a major concern for policymakers. Both 
policymakers and insurers share an interest in reducing waste to 
control these costs.
In Korea, the National Health Insurance Service (NHIS) pro-
gram operates as a single-payer system. At the initiation of this 
program, the NHIS paid reimbursements to health care providers 
that submitted claims for medically necessary services or items. 
However, this system relied upon the judgments of healthcare pro-
viders regarding the necessity and appropriateness of the care pro-
vided. The system was vulnerable to fraud by unscrupulous pro-
viders claiming inappropriate medical costs for personal profit. 
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Under these circumstances, fraud was considered to be one cause 
of increasing healthcare expenditures [5,6]. To reduce inappropri-
ate healthcare expenditures and promote the appropriate submis-
sion of insurance claims, the government instituted annual medi-
cal insurance fraud investigations since 2003. To detect occur-
rences of fraud and abuse, insurance claims are reviewed and used 
to identify suspicious medical institutions for targeted claims re-
views [7-9]. Target organizations for these claims reviews include 
all types of medical institutions. Approximately 1% of all medical 
institutions undergo targeted fraud investigation annually.
Previous research suggests that fraud investigation is important 
for reducing waste in healthcare expenditures [10-13]. In addition, 
researchers have looked at methods for discouraging fraud 
schemes [14-16]. Although fraud investigation results are pub-
lished regularly in government reports, these provide only the 
amounts of the fraudulent costs recovered and the penalties im-
posed on the target institutions. Whether fraud investigations 
have had a broader effect on healthcare costs is not clear. Korea has 
a highly competitive medical environment, and collaborative net-
works have been established as a strategy to survive in this dy-
namic environment [17]. Given the pressures of the healthcare en-
vironment and the interconnectedness of institutions, we hypoth-
esized that fraud investigations might have impacts even on the 
practices of medical institutions not targeted for investigation, and 
that these effects might impact medical institutions of all sizes, 
ranging from clinics to long-term care facilities and hospitals.
Thus, the aim of our study was to assess the effects of fraud in-
vestigations on medical costs. We assumed that changes in the 
claim pattern, such as a reduction in inappropriate or fraudulent 
claims, will result in a change in medical expenditure after a fraud 
investigation, and that these changes will be impacted not only by 
target medical institutions but also by other medical institutions. 
In addition, we evaluated whether the effects of fraud investiga-
tions varied according to the type of medical institution.
METHODS
1. Database and data collection
To investigate the effects of fraud investigation on medical insti-
tutions, we reviewed data published for medical fraud investiga-
tions conducted between 2010 and 2014, monthly aggregated Na-
tional Health Insurance (NHI) claims data to hospital level from 
July 2009 to May 2015, and national medical institution data. First, 
we selected a non-target organization for evaluating the effects of 
medical fraud investigations using the nationwide medical institu-
tion registry. In Korea, the administrative districts consist of 17 
geopolitical areas that are further divided into 257 municipal dis-
tricts (called si-gun-gu). In our study, region was defined according 
to the municipal districts. Propensity score matching (ratio=1:3) 
was used to select non-target organization by matching medical 
institutions annually based on information of target organization. 
Since we assumed that the effects of the fraud investigation would 
be in the same or nearby medical institution, we used information 
from region, institution type, and ownership status. Second, we 
matched medical institution data with NHI claims data for medi-
cal institutions that had been the focus of on-site investigations 
(target organizations). Between 2010 and 2014, a total of 2,505 on-
site investigations of medical institutions were performed. The 
month of investigation was defined as the index month and varied 
by medical institution, occurring between 2010 and 2014. We then 
selected periods of 12 months before and after based on the index 
month of the on-site investigation for several reasons. (1) We want-
ed to reduce any possible confounding effect due to other investiga-
tions. Each on-site investigation was performed continuously 
throughout the month, and there was a possibility that long obser-
vation periods (over 12 months) would overlap with investigations 
taking place in the surrounding years, meaning that the general 
trends could be affected by other investigations. (2) There was a 
possibility of switching from the target organization to a non-tar-
get organization. (3) We considered the punishment of the fraud 
investigation. According to the type of fraud, the medical institute 
received a form of suspension, meaning that there was no claim 
from the medical institute during this period. For these reasons, we 
limited the observational period to within 12 months based on the 
on-site investigation. Third, we created a single index date and 
month for the target organization by institution type and region. 
Fourth, we then selected a non-target organization from the same 
period as the target organization, matched according to institution 
type, ownership status and region. Non-target organizations were 
classified as being from the same or other region. Same-region fa-
cilities were those from the same area as the on-site investigation in 
the index year. Other regions were defined as areas that did not 
have on-site investigations within their geopolitical boundaries 
and in which fraud had never been detected. Finally, we excluded 
medical institutions with incomplete period data. A total of 20,625 
medical institutions (1,614 target institutions and 19,011 non-target 
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institutions) were included in the analysis of changes in medical 
costs per month (Figure 1A).
2. Variables
To evaluate the effects of fraud investigations, the outcome vari-
able in our study was healthcare costs per medical institution. 
Cost data was obtained from the NHI claims database per month 
and included the combined costs of inpatient and outpatient care. 
There is no data related to patient information. Outpatient costs 
included all health service costs except medication, due to the 
adoption of separate prescribing and dispensing drug systems in 
South Korea. Inpatient costs included reimbursements for health 
services, including medications. In addition, uncovered benefits 
were not included in our data. Uninsured benefits were not reim-
bursed by the NHI system; thus, this information was not includ-
ed in the claim data. We have adjusted total price inflation. In oth-
er words, it looks like the total cost ratio has remained unchanged 
by 2014.
The primary variable of interest in this study was the level of 
cost change in organizations targeted for fraud investigation and 
overall change trend after fraud investigation. The period of fraud 
investigation of the medical institutions studied varied by index 
date, so we created a dummy variable for unified time. We used 
the dummy variable based on the index date to denote the time 
before and after, ranging from 12 months before to 12 months af-
ter investigation (–12 to 12, respectively). To investigate the chang-
es in cost per medical institution following fraud investigation, the 
time before the fraud investigation was defined as zero, and the 
time after the investigation concluded was defined as one. In addi-
tion, our analysis of trends looked at linear changes after investiga-
tion. Baseline trends varied by the index date of fraud investiga-
tion and include data from July 2009 to May 2015.
We adjusted the data for other medical institution characteris-
tics when analyzing the changes in costs after fraud investigation. 
Human resources data (doctors, nurses), institution type (clinic, 
long-term care, hospital), medical institution ID, total patients per 
medical facility, proportion of medical aid patients, number of 
fraud investigation per region, number of fraud detections per re-
gion, medical service department, and year were included in our 
analysis.
3. Statistical analysis
The distribution of each categorical variable was examined by 
an analysis of frequencies and percentages, and χ2 tests were per-
formed. Analysis of variance was also performed to compare aver-
age values and standard deviations for the continuous variables. 
To evaluate the changes in cost after fraud investigation, we used 
an interrupted time series study design using generalized estimat-
ing equations (GEE) by target organization [18-21]. In this study, 
the error term for GEE with correlation structure was autoregres-
sive (AR1) and used repeated outcome measurement. We used log 
transformations on costs to reflect the original scale of skewed 
data and to measure changes in the dependent variables in re-
sponse to percentage changes in the explanatory variable [22-25]. 
In addition, subgroup analyses were performed by institution 
type. All statistical analyses were performed using SAS ver. 9.4 
(SAS Institute Inc., Cary, NC, USA). All p-values less than 0.05 
were considered to indicate statistical significance.
Figure 1. Changes in average medical expenditure before and after fraud investigation by type of hospital. Data is shown as mean cost per 
medical institution. Medical institutions that did not receive fraud investigations were classified as non-target organizations (same region, other 
region). Data was based on National Health Insurance claim data. (A) Clinic. (B) Long-term care facilities. (C) Hospital.
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RESULTS
The data we used in our study consisted of 20,625 medical insti-
tutions. Among these, 1,614 of the included sites were target orga-
nizations for fraud investigations and 19,011 were non-target orga-
nizations (same region, 12,236; other region, 6,775). Among the 
included sites, 16,731 (81.12%) were clinics, 1,993 (9.66%) were 
long-term care facilities, and 1,901 (9.22%) were hospitals. Mean 
medical costs per month were highest in target organizations (164 
million Korean won [KRW]) and lowest in non-target organiza-
tions located in same region (77 million KRW) (Table 1).
The overall trend of average cost per month seemed to be in-
creasing in clinics and long-term care facilities in both target and 
non-target organizations before fraud investigation began. After 
fraud investigation, the general trend of average cost decreased in 
the target organizations. In addition, a similar trend was observed 
Table 1. General characteristics of hospital (n= 20,625)     
Characteristic
Fraud investigation
Total p-value
Done
None
Same region Other region
Institution type
Clinic
Long-term care facilities
Hospital
  
1,059 (6.33)
305 (15.30)
250 (13.15)
  
11,006 (65.78)
643 (32.26)
587 (30.88)
  
4,666 (27.89)
1,045 (52.43)
1,064 (55.97)
  
16,731 (81.12)
1,993 (9.66)
1,901 (9.22)
< 0.0001
  
  
  
Medical cost* 164.98± 222.47 77.12± 135.92 141.86± 210.81 100.38± 168.12 < 0.0001
No. of doctors 2.21± 2.66 1.56± 1.90 2.27± 3.27 1.85± 2.52 < 0.0001
No. of nurses 4.56± 9.67 1.83± 6.31 4.54± 10.41 2.94± 8.27 < 0.0001
Patients per medical institution 1,867± 1,810 1,875± 1,580 1,947± 1,800 1,898± 1,674 0.014
No. of fraud investigation per region 2.66± 1.88     2.66± 1.88   
No. of detected fraud per region 1.92± 1.85     1.92± 1.85   
Proportion of medical aid 13.7± 14.57 7.75± 9.55 10.72± 12.45 9.19± 11.19 < 0.0001
Medical service department
General practitioner
Internal medicine
Neurology
Psychiatry
Surgery department
Orthopedics
Neurosurgery
Cardiothoracic surgery
Anesthesia
Obstetrics and gynecology
Pediatrics
Ophthalmology
Otorhinolaryngology
Dermatology
Urology
Radiology
Laboratory medicine
Rehabilitation
Nuclear medicine
Family medicine
None†
  
658 (9.98)
155 (6.07)
7 (5.51)
68 (7.52)
39 (5.50)
109 (6.99)
22 (7.51)
1 (3.23)
31 (6.61)
38 (4.99)
26 (3.32)
30 (3.78)
39 (4.32)
21 (3.52)
12 (2.02)
7 (4.90)
1 (25.00)
17 (5.63)
1 (33.33)
27 (5.29)
305 (15.30)
  
3,546 (53.77)
1,731 (67.83)
83 (65.35)
602 (66.59)
451 (63.61)
1,044 (66.97)
194 (66.21)
16 (51.61)
293 (62.47)
522 (68.50)
522 (66.75)
540 (68.01)
605 (67.00)
419 (70.18)
409 (68.97)
101 (70.63)
3 (75.00)
175 (57.95)
2 (66.67)
335 (65.69)
643 (32.26)
  
2,391 (36.25)
666 (26.10)
37 (29.13)
234 (25.88)
219 (30.89)
406 (26.04)
77 (26.28)
14 (45.16)
145 (30.92)
202 (26.51)
234 (29.92)
224 (28.21)
259 (28.68)
157 (26.30)
172 (29.01)
35 (24.48)
0
110 (36.42)
0
148 (29.02)
1,045 (52.43)
  
6,595 (31.98)
2,552 (12.37)
127 (0.62)
904 (4.38)
709 (3.44)
1,559 (7.56)
293 (1.42)
31 (0.15)
469 (2.27)
762 (3.69)
782 (3.79)
794 (3.85)
903 (4.38)
597 (2.89)
593 (2.88)
143 (0.69)
4 (0.02)
302 (1.46)
3 (0.01)
510 (2.47)
1,993 (9.66)
< 0.0001
  
  
  
  
  
    
  
  
  
  
  
  
  
  
    
  
  
  
  
  
  
Year‡
2010
2011
2012
2013
2014
  
344 (8.14)
361 (8.78)
251 (6.21)
292 (6.95)
366 (9.04)
  
2,711 (64.14)
2,459 (59.83)
2,176 (53.87)
2,425 (57.72)
2,465 (60.89)
  
1,172 (27.73)
1,290 (31.39)
1,612 (39.91)
1,484 (35.32)
1,217 (30.06)
  
4,227 (20.49)
4,110 (19.93)
4,039 (19.58)
4,201 (20.37)
4,048 (19.63)
< 0.0001
Total 1,614 (7.10) 12,236 (53.85) 6,775 (32.85) 20,625 (100.00)
Values are presented as number (%) or mean± standard deviation.     
*Korean won (unit: 1 million). †‘None’ indicates long-term care. ‡Index year of fraud investigation.   
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in non-target organizations, including long-term care facilities of 
the same region and hospitals located in other regions (Figure 1).
The interrupted analysis of medical cost and average cost per 
month also showed changes after fraud investigation. The level of 
change that existed in target organizations (–1.40%, p<0.001) and 
non-target organizations (same region: –0.15%, p= 0.2720; other 
regions: 0.18%, p= 0.2993) demonstrated statistical significance 
for target organizations. In addition, a significant trend for re-
duced costs after fraud investigation existed in both target organi-
zations and non-target organizations (target, –0.33%; non-target/
same region, –0.19%; non-target/other regions, –0.17%) (Figure 2).
Subgroup analyses by institution type for level change and trend 
change were performed for both target and non-target organiza-
tions. In the case of clinics, significant differences in level change 
were observed for target organizations (target, –1.55%; non-target/
same region, –0.15%; non-target/other regions, 0.01%). The trend 
change tended to decrease for both target and non-target organi-
zations (target, –0.20%; non-target/same region, –0.15%; non-tar-
get/other region, –0.12%). Among long-term care facilities, signifi-
cant level changes existed for both target and non-target organiza-
tions located in the same region (target, –1.11%; non-target, 
–0.84%). Trend changes after fraud investigation existed for both 
target organizations (–0.46%) and non-target organizations (same 
region, –0.75%; other regions, –0.78%). Among hospitals, level 
changes were statistically significant for non-target organizations 
of the same region (1.38%). The general trend of average cost per 
month decreased after fraud investigation (Table 2).
DISCUSSION
In this study, we evaluated the effects of fraud investigations on 
healthcare costs in both organizations targeted for medical fraud 
investigations and non-target organizations. We found that fraud 
investigations were associated with reductions in healthcare costs 
not only at target organizations but also at non-target organiza-
tions. Prior to fraud investigations, both target and non-target or-
ganizations had a tendency to raise monthly medical costs. This 
trend has changed based on the time of the fraud investigations, 
and the target institution has decreased costs at the time of investi-
gation. Furthermore, the cost trend after fraud investigation tend-
ed to decrease in target and non-target organizations. These re-
duced costs per month could be considered direct effects of the 
target organization investigation. Medical institutions that have 
undergone a fraud investigation would be expected to modify 
their insurance claim practices to ensure accurate claim submis-
sions for health services delivered in their facilities. These changes 
would be expected to result in decreasing medical costs per month 
after fraud investigations identified inappropriate insurance 
Table 2. Subgroup analysis of change in medical expenditure after 
intervention by institution type 
Fraud investigation
Change in level Change in slope
Estimates± SE p-value Estimates± SE p-value
Clinic
Done
None
Same region
Other region
  
–0.0155± 0.0039
  
–0.0015± 0.0015
0.0001± 0.0018
  
< 0.0001
  
0.3069
0.9751
  
–0.002± 0.0009
  
–0.0015± 0.0003
–0.0012± 0.0004
  
0.0235
  
< 0.0001
0.0031
Long-term care facilities
Done
None
Same region
Other region
  
–0.0111± 0.0047
  
–0.0084± 0.0036
–0.0067± 0.0045
  
0.0169
  
0.0204
0.1405
  
–0.0046± 0.0019
  
–0.0075± 0.0018
–0.0078± 0.0016
  
0.0134
  
< 0.0001
< 0.0001
Hospital
Done
None
Same region
Other region
  
0.0016± 0.0085
  
0.0138± 0.0057
–0.0026± 0.0049
  
0.8488
  
0.0152
0.5912
  
–0.0020± 0.0022
  
–0.0035± 0.0020
–0.0059± 0.0012
  
0.3567
  
0.0869
< 0.0001
Estimates are the results of log transformation and interpretable as percentage chang-
es. Adjusted for type of hospital, number of doctors, number of nurses, patients per 
hospital, number of fraud investigation per region, number of detected fraud per region, 
proportion of medical aid, year, and region.
SE, standard error. 
Figure 2. The results of predicted cost before and after fraud investi-
gation for each group. Adjusted for type of hospital, number of doc-
tors, number of nurses, patient per medical institute, number of 
fraud investigations per region, number of detected fraud per re-
gion, proportion of medical aid, medical service department, year, 
and region. Data was analyzed based on the data of National Health 
Insurance claim. *Statistically significant.
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claims. In addition, a ripple effect could exist for non-target orga-
nizations where the occurrence of a fraud investigation might mo-
tivate examination of claims practices. There may be a variety of 
unmeasured factors that can affect the cost of a medical institu-
tion. However, it is difficult to explain the change in trends in non-
target institutions that have various points of time based on the 
specific time point of fraud investigation. Plausible explanations 
for these phenomena can be associated with the medical industry 
in Korea [17,26], where medical institutions have developed col-
laborative networks as a strategy to deal with the highly competi-
tive environment. Investigators think there will be a potential im-
pact of fraud investigations, and information about fraud investi-
gation is expected to spread to other medical institutions that are 
not subject to investigation. As a result, a single fraud investigation 
could have broader effects in decreasing costs due to inappropriate 
insurance claims. In addition, non-target organizations in the 
same region as target organizations would be expected to show a 
reduction in costs after fraud investigation faster than non-target 
organizations in other regions.
The results of the sub-group analysis show that the magnitude 
of impact differed depending on type of institution. Careful inter-
pretation of the results is needed, as they do not represent the ab-
solute scale of the effect of the fraud investigation; rather, the scale 
is relative and may change. This means that the results cannot be 
used to compare each group. One plausible explanation for the 
magnitude of the effect would be that it is associated with a differ-
ence in the type and size of illegal insurance claims submitted for 
hospital-level care. Clinics are the smallest medical institutions in-
cluded in this analysis and provide primary care services to pa-
tients. Long-term care and hospital facilities are larger and must 
meet certain criteria, including having over 30 beds for inpatient 
care. Long-term care institutions provide health services only to 
stable, residential elderly patients. By contrast, hospitals provide a 
range of medical services through multiple departments. Thus, 
the size of illegal insurance claims would be expected to be largest 
in hospitals compared with other institutions. However, the sum 
of reduced costs would be expected to be largest when clinic costs 
are combined, as these represent the largest percentage of medical 
facilities.
Fraud investigation is an important approach for protecting 
health expenditures from waste. However, fraud investigations in 
Korea are performed for only approximately 1% of all medical in-
stitutions annually due to limited resources. The effectiveness of 
fraud investigations would be expected to increase with a greater 
number of investigations. In Korea, methods of medical fraud in-
clude document investigations, data analysis and field investiga-
tions, and most investigations are conducted in field investigations 
using human experts. However, human resources for these re-
views are limited, and these investigations are not conducted for a 
large number of institutions. Thus, methods for improving fraud 
investigation efficiency and discouraging medical fraud are great-
ly needed. Like other countries, there has been an attempt to adopt 
data analysis for fraud detection [27-29], but fewer medical institu-
tions are detected in this way due to their low accuracy. To develop 
better fraud detection systems, specialized training and time are 
needed to further improve current administrative processes. Im-
proving methods for fraud detection and prevention would re-
quire increasing the number of investigations, as well as maximiz-
ing the effects of fraud investigations. Thus, policymakers focusing 
on healthcare fraud should consider both their human resource 
plan and pursue improvements in fraud investigation methods. In 
addition, a systematic long-term plan for fraud prevention should 
include data analysis on the accuracy of fraud investigations and 
their outcomes.
There are several strengths in the study. First, to the best of our 
knowledge, our study is the first to evaluate the impact of fraud in-
vestigations on costs in both target and non-target organizations. 
Previous research and reports have considered the actual effects of 
investigations, such as penalties and redemptions [13], but no prior 
study has performed an analysis of the effects of fraud investiga-
tions on overall changes in costs per month after investigation. 
Second, our results provide valuable evidence to policymakers re-
garding the effects of fraud investigations. Our study characterizes 
both direct and ripple effects of fraud investigations on healthcare 
costs and billing practices. Thus, it would be meaningful for poli-
cymakers to consider our findings when evaluating ongoing plans 
for healthcare fraud investigations. Third, this study provides evi-
dence related to the expansion of fraud investigations. Expansion 
of fraud investigations through a variety of methods, such as the 
prediction of fraud, may contribute to the reduction of inappropri-
ate medical costs. However, selecting and expanding these meth-
ods will require careful consideration.
Despite these strengths, our study does have some limitations. 
First, the data used in our study included only medical institution 
characteristics, and we were unable to consider patient character-
istics, such as demographic factors, disease severity, and length of 
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stay. Medical costs are influenced by patient factors, particularly 
severity of disease, health services utilization, and other potential 
factors [30-32]. However, as our data did not include patient infor-
mation, we could not control for these factors. We did adjust for 
health service department type to account for differences between 
medical institutions that might result from differences in the types 
of patients being treated in each facility. Second, target organiza-
tions chosen for investigation of possibly fraudulent activities in-
cluded only approximately 1% of all medical institutions. This 
limited sample lacks generalizability to all institutions. There may 
also be an error in selecting a non-target medical institution, and 
this can be a potential bias in our study results. In addition, we did 
not investigate whether the effects of fraud investigations might be 
different for other large medical institutions compared with small 
medical institutions. However, this study was the first attempt to 
evaluate cost changes for target organizations after fraud investi-
gation, and our results provide meaningful information to policy-
makers seeking to protect health expenditures from fraud. Third, 
we could not consider unmeasured factors that may affect fraud 
investigations, such as the personal characteristics of individual 
investigators. The data used in our study did not include investiga-
tion team members’ employment histories or years of working on 
fraud investigations. These factors also might affect the methods 
of investigation used for each medical institute and thereby impact 
changes in medical costs after investigation. In addition, although 
we selected non-target organizations annually, there was a possi-
bility of overlaps within the study period. To minimize study peri-
od overlaps, we limited the period of analysis to 12 months before 
and after the occurrence of an investigation. Also, non-target or-
ganizations were selected based on 257 municipal districts within 
the 17 geopolitical boundaries. Finally, we did not evaluate unin-
sured benefits, which were not included in our dataset. Thus, we 
were unable to measure the change in uninsured benefits and oth-
er undocumented costs.
In conclusion, our results support the efficacy of fraud investiga-
tions for protecting healthcare expenditures. The impact of the 
fraud investigations on reducing costs was observed not only for 
target organizations but also for non-target organizations. Our 
findings highlight the need for increasing the number of fraud in-
vestigations to maximize their effects. Thus, policymakers should 
consider the available workforce for conducting these investiga-
tions as well as alternative methods for fraud investigation to 
achieve maximal effects.
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